{"id":27,"date":"2016-10-10T05:57:54","date_gmt":"2016-10-10T05:57:54","guid":{"rendered":"http:\/\/www.sathguru.com\/news\/?p=27"},"modified":"2021-04-02T06:37:04","modified_gmt":"2021-04-02T06:37:04","slug":"biosimilars-how-can-we-realize-the-240-bn-opportunity","status":"publish","type":"post","link":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/","title":{"rendered":"Biosimilars \u2013 How can we realize the $ 240 Bn Opportunity"},"content":{"rendered":"<p>[vc_row][vc_column][vc_column_text]The knowledge paper can be downloaded at <a href=\"https:\/\/www.sathguru.com\/Publication\/download\/Biosimilars-WhitePaper-report.pdf\">Biosimilars<\/a><\/p>\n<p>The domestic pharma industry can take advantage of the $240-billion global opportunity for biosimilars, according to a report of Assocham and Sathguru Management Consultants. The report was released by D Swaminadhan, President &amp; Director General, Jawaharlal Nehru Institute of Advanced Studies, at conference on biopharma held here on Thursday.<\/p>\n<p>\u201cWith the introduction of a new regulatory policy in India and increased affordability that biosimilars offer, the domestic market is expected reach the target of $40 billion by 2030 to command a 20 per cent share of the global market,\u201d the report added. The Indian biosimilars industry was close to $300 million in 2015. Domestic sales, estimated at $250 million, grew at a CAGR of 14 per cent while exports contributed the balance.<\/p>\n<p>Biosimilars, or follow-on biologics, are terms used to describe officially approved new versions of innovator biopharmaceutical products following patent expiry.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_single_image image=&#8221;28&#8243;][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_column_text]The knowledge paper can be downloaded at Biosimilars The domestic pharma industry can take advantage of the $240-billion global opportunity for biosimilars, according to a report of Assocham and Sathguru Management Consultants. The report was released by D Swaminadhan, President &amp; Director General, Jawaharlal Nehru Institute of Advanced Studies, at conference on biopharma held here [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":28,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":["post-27","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publications"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Biosimilars \u2013 How can we realize the $ 240 Bn Opportunity<\/title>\n<meta name=\"description\" content=\"Biosimilars, or follow-on biologics, are terms used to describe officially approved new versions of innovator biopharmaceutical products following patent expiry.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biosimilars \u2013 How can we realize the $ 240 Bn Opportunity\" \/>\n<meta property=\"og:description\" content=\"Biosimilars, or follow-on biologics, are terms used to describe officially approved new versions of innovator biopharmaceutical products following patent expiry.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/\" \/>\n<meta property=\"og:site_name\" content=\"Sathguru News\" \/>\n<meta property=\"article:published_time\" content=\"2016-10-10T05:57:54+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-04-02T06:37:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/Biosimilars-06-10-16.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"427\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"sadmin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@sathgurumc\" \/>\n<meta name=\"twitter:site\" content=\"@sathgurumc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"sadmin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biosimilars \u2013 How can we realize the $ 240 Bn Opportunity","description":"Biosimilars, or follow-on biologics, are terms used to describe officially approved new versions of innovator biopharmaceutical products following patent expiry.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/","og_locale":"en_US","og_type":"article","og_title":"Biosimilars \u2013 How can we realize the $ 240 Bn Opportunity","og_description":"Biosimilars, or follow-on biologics, are terms used to describe officially approved new versions of innovator biopharmaceutical products following patent expiry.","og_url":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/","og_site_name":"Sathguru News","article_published_time":"2016-10-10T05:57:54+00:00","article_modified_time":"2021-04-02T06:37:04+00:00","og_image":[{"width":640,"height":427,"url":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/Biosimilars-06-10-16.jpg","type":"image\/jpeg"}],"author":"sadmin","twitter_card":"summary_large_image","twitter_creator":"@sathgurumc","twitter_site":"@sathgurumc","twitter_misc":{"Written by":"sadmin","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/#article","isPartOf":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/"},"author":{"name":"sadmin","@id":"https:\/\/www.sathguru.com\/news\/#\/schema\/person\/3e1fb591be3f42bc88c681ee61ab007a"},"headline":"Biosimilars \u2013 How can we realize the $ 240 Bn Opportunity","datePublished":"2016-10-10T05:57:54+00:00","dateModified":"2021-04-02T06:37:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/"},"wordCount":177,"commentCount":0,"publisher":{"@id":"https:\/\/www.sathguru.com\/news\/#organization"},"image":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/Biosimilars-06-10-16.jpg","articleSection":["Publications"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/","url":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/","name":"Biosimilars \u2013 How can we realize the $ 240 Bn Opportunity","isPartOf":{"@id":"https:\/\/www.sathguru.com\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/#primaryimage"},"image":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/#primaryimage"},"thumbnailUrl":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/Biosimilars-06-10-16.jpg","datePublished":"2016-10-10T05:57:54+00:00","dateModified":"2021-04-02T06:37:04+00:00","description":"Biosimilars, or follow-on biologics, are terms used to describe officially approved new versions of innovator biopharmaceutical products following patent expiry.","breadcrumb":{"@id":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/#primaryimage","url":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/Biosimilars-06-10-16.jpg","contentUrl":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/Biosimilars-06-10-16.jpg","width":640,"height":427},{"@type":"BreadcrumbList","@id":"https:\/\/www.sathguru.com\/news\/2016\/10\/10\/biosimilars-how-can-we-realize-the-240-bn-opportunity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.sathguru.com\/news\/"},{"@type":"ListItem","position":2,"name":"Biosimilars \u2013 How can we realize the $ 240 Bn Opportunity"}]},{"@type":"WebSite","@id":"https:\/\/www.sathguru.com\/news\/#website","url":"https:\/\/www.sathguru.com\/news\/","name":"Sathguru News","description":"Sathguru News","publisher":{"@id":"https:\/\/www.sathguru.com\/news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.sathguru.com\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.sathguru.com\/news\/#organization","name":"sathguru Management Consultants","url":"https:\/\/www.sathguru.com\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sathguru.com\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/Sathguru-logo.png","contentUrl":"https:\/\/www.sathguru.com\/news\/wp-content\/uploads\/2017\/04\/Sathguru-logo.png","width":180,"height":83,"caption":"sathguru Management Consultants"},"image":{"@id":"https:\/\/www.sathguru.com\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/sathgurumc","https:\/\/www.linkedin.com\/company\/sathguru-management-consultants","https:\/\/www.youtube.com\/user\/SathguruConsultants"]},{"@type":"Person","@id":"https:\/\/www.sathguru.com\/news\/#\/schema\/person\/3e1fb591be3f42bc88c681ee61ab007a","name":"sadmin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.sathguru.com\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/028fee43c618fecdf419f8b5e2b991874271dfa82e49a8fc0ff51997d3c1ee41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/028fee43c618fecdf419f8b5e2b991874271dfa82e49a8fc0ff51997d3c1ee41?s=96&d=mm&r=g","caption":"sadmin"}}]}},"_links":{"self":[{"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/posts\/27","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/comments?post=27"}],"version-history":[{"count":5,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/posts\/27\/revisions"}],"predecessor-version":[{"id":2116,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/posts\/27\/revisions\/2116"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/media\/28"}],"wp:attachment":[{"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/media?parent=27"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/categories?post=27"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.sathguru.com\/news\/wp-json\/wp\/v2\/tags?post=27"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}